Small Lymphocytic Leukemia
11
0
0
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
27.3%
3 terminated out of 11 trials
62.5%
-24.0% vs benchmark
9%
1 trials in Phase 3/4
80%
4 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (11)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia